FCP OP MEDICAL BioHealth Trends FCP OP ... - Sal. Oppenheim
FCP OP MEDICAL BioHealth Trends FCP OP ... - Sal. Oppenheim
FCP OP MEDICAL BioHealth Trends FCP OP ... - Sal. Oppenheim
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
HEALTHCARE MARKET<br />
Biotech: Large Caps largely depleted<br />
MARKET CAPITALISATION BIOTECH-SECTOR IN 2001 AND TAKE-OVERS<br />
Sonstige Other<br />
42%<br />
AMGN<br />
23%<br />
DNA 10%<br />
GENZ 4%<br />
IMNX 5%<br />
ABI 2%<br />
CHIR 3%<br />
MLNM<br />
IDHP 3%<br />
2% BGEN 3%<br />
MEDI 3%<br />
Source: Credit Suisse First Boston As of: 26.11.2001<br />
YYear Ti Ticker k TTarget-Company t C BBuyer<br />
2010 GENZ Genzyme Sanofi<br />
2009 DNA Genentech Roche<br />
2008 MLNM Millennium Takeda<br />
2008 ABI Applied Biosciences Invitrogen<br />
2007 MEDI Mediummune AstraZeneca<br />
2006 CHIR Chiron Novartis<br />
2003 IDHP Idec Biogen<br />
2002 IMNX Immunex Amgen<br />
� Number of US-Large Caps were largely depleted by take-overs over the last couple of years<br />
� Funds within the peer group loose their investment candidates and enter unknown territory<br />
06/30/2012| Page 14 <strong>Oppenheim</strong> Asset Management Services S.à r.l.
Change language